CLL Studies Presented at the 2016 Hematology Meeting Confirm Ibrutinib ’s Long-term Efficacy and Suggest Benefit From Second-line Agents
Discussion - Do you know how recent CLL results presented at ASH 2016 could change your practice? Read my thoughts on ibrutinib and what to do after treatment failure. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - January 6, 2017 Category: Hematology Source Type: research
Novel Agents in Clinical Trials for AML
Video - In this on-demand Webcast, Richard M. Stone, MD, provides expert perspective on optimal treatment of patients with acute myeloid leukemia. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - January 6, 2017 Category: Hematology Source Type: research
Current Management of Relapsed Acute Myeloid Leukemia
Video - In this on-demand Webcast, Harry P. Erba, MD, provides expert perspective on optimal treatment of patients with acute myeloid leukemia. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - January 6, 2017 Category: Hematology Source Type: research
Best Treatment Options for Patients With Newly Diagnosed AML
Video - In this on-demand Webcast, B. Douglas Smith, MD, provides expert perspective on optimal treatment of patients with acute myeloid leukemia. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - January 6, 2017 Category: Hematology Source Type: research
Emerging Predictive and Prognostic Factors for AML
Video - In this on-demand Webcast, Keith W. Pratz, MD, provides expert perspective on optimal treatment of patients with acute myeloid leukemia. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - January 6, 2017 Category: Hematology Source Type: research
Leukemias
Slideset - In this downloadable slideset, Elias Jabbour, MD, and Farhad Ravandi, MD, review key studies and data presented at the 2016 American Society of Hematology annual meeting relevant to the management of patients with acute or chronic leukemias. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 20, 2016 Category: Hematology Source Type: research
Ponatinib Plus Hyper-CVAD Active as Frontline Therapy in Ph+ ALL
Slideset - In this phase II open-label study, the combination of ponatinib with hyper-CVAD resulted in high complete cytogenetic and molecular response rates in patients with Ph+ ALL. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 12, 2016 Category: Hematology Source Type: research
ELIANA: CTL019 Shows High CR Rate in Pediatric/Young Adult Patients With Relapsed/Refractory B-Cell ALL
Slideset - Phase II trial suggests durable, MRD-negative CR in 82% of patients after infusion of CTL019 CAR T-cells. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 9, 2016 Category: Hematology Source Type: research
Phase III EURO-SKI: Cessation of TKI Therapy Safe, Feasible for Pts Who Achieve Deep Molecular Response
Slideset - Factors associated with MRFS after TKI cessation included longer durations of imatinib therapy, MR4, and pretreatment IFN. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 9, 2016 Category: Hematology Source Type: research
Novel Agents in Clinical Trials for AML
Slideset - In this downloadable slideset, Richard M. Stone, MD, reviews the key data regarding promising investigational agents in clinical trials for acute myeloid leukemia. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 9, 2016 Category: Hematology Source Type: research
Current Management of Relapsed Acute Myeloid Leukemia
Slideset - In this downloadable slideset, Harry P. Erba, MD, PhD, reviews the key data regarding current management of patients with relapsed acute myeloid leukemia. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 8, 2016 Category: Hematology Source Type: research
Best Treatment Options for Patients With Newly Diagnosed AML
Slideset - In this downloadable slideset, B. Douglas Smith, MD, reviews the key data regarding optimal management of patients with newly diagnosed acute myeloid leukemia. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 8, 2016 Category: Hematology Source Type: research
Phase III SWOG S1203: Idarubicin + High-Dose Cytarabine ± Vorinostat vs Standard Therapy in Newly Diagnosed AML
Slideset - In this phase III trial, idarubicin plus high-dose cytarabine with or without vorinostat did not show superiority to 7 + 3 regimen in untreated AML patients 60 years of age or younger. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 8, 2016 Category: Hematology Source Type: research
Management of CLL in the Frail Patient
Slideset - In this downloadable slideset, Andrew D. Zelenetz, MD, PhD, presents slides examining the management of CLL in treatment-naive and relapsed/refractory frail patients. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 8, 2016 Category: Hematology Source Type: research
Vadastuximab Talirine + Hypomethylating Agents Active and Well Tolerated in Untreated Older Patients With AML
Slideset - In this phase I trial, vadastuximab talirine plus HMA was active in higher-risk patient subsets, including patients with advanced secondary AML and those older than 75 years of age. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 8, 2016 Category: Hematology Source Type: research
